Key facts
- Coherence’s last known valuation is $9.6M (Mar 2023).
- It has raised $12.3M; the latest was Early Stage VC ($10.0M) in Nov 2025.
- Notable investors include Creative Destruction Lab, University of Toronto, University of Toronto Entrepreneurship, Artesian, Blackbird Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Coherence
- ·The full record, as it builds
Funding rounds
No funding rounds for Coherence are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Coherence
Developer of minimally invasive implants designed to help tackle serious medical conditions. The company through its technology research, development, and clinical testing offers effective and miniaturized implants, its neural interfaces are designed to enable new treatment possibilities with minimal surgery, extract high-fidelity electrical information from the body, using machine learning to derive neural biomarkers associated with patient-specific disease state and treatment efficacy, enabling healthcare professionals to improve the lives of patients suffering from neurological disorders.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2022
- Employees
- 16
- Website
- coherenceneuro.com/
- Ownership
- Privately Held (backing)
Coherence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Coherence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Coherence in its N-PORT filings yet. We sweep new filings monthly.